Emcure Pharmaceuticals Limited (BOM:544210)

India flag India · Delayed Price · Currency is INR
1,445.90
-8.65 (-0.59%)
At close: Mar 2, 2026
45.20%
Market Cap 273.99B
Revenue (ttm) 88.50B
Net Income (ttm) 8.70B
Shares Out n/a
EPS (ttm) 45.90
PE Ratio 31.50
Forward PE 24.99
Dividend 3.00 (0.21%)
Ex-Dividend Date Aug 14, 2025
Volume 5,433
Average Volume 6,632
Open 1,399.25
Previous Close 1,454.55
Day's Range 1,390.00 - 1,451.40
52-Week Range 890.00 - 1,585.50
Beta n/a
RSI 45.33
Earnings Date Feb 4, 2026

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop... [Read more]

Industry Pharmaceutical Preparations
Founded 1981
Employees 6,731
Stock Exchange Bombay Stock Exchange
Ticker Symbol 544210
Full Company Profile

Financial Performance

In fiscal year 2025, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.

Financial Statements

News

There is no news available yet.